Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland , Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity™ Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as …

NEW YORK, Oct. 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Tronox Holdings plc (NYSE: TROX) between February 12, 2025 and July 30, 2025, both dates inclusive (the “Class Period”), of the important November 3, 2025 lead plaintiff deadline.

Penumbra unveiled the results of a study on Sunday showing its device is superior to blood thinners in pulmonary embolism patients.

Earnings from Apple, Amazon, Alphabet, Meta, and Microsoft are set to dominate market attention over the Fed's expected rate cut. Strong AI-driven enterprise demand is fueling optimism for MSFT, GOOG, and AMZN.

DaVita's recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.

Amploius Wealth sold 25,217 shares of ACWI for an estimated $3.3 million based on the average share price for the third quarter. The transaction represents about 0.3% of 13F reportable assets under management for the period.

NEW YORK , Oct. 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Gold "doesn't seem like it has any chance of slowing down," says Will Rhind. He points a likely run-up to several factors, from a weakening dollar, to persistent inflation, to central banks around the global loading up on the rare metal.

Las Vegas Sands' Q3 sales and earnings crushed the market's expectations. Performance for the company's Marina Bay property was particularly strong.

The S&P 500 (SPY) often has conflicting technical signals, but last week's action provided a clear bullish bias. This could change quickly, and next week's geopolitical events create a high-risk environment.

CoreWeave's stock movements this past week were connected to the company's proposed buyout of Core Scientific. The proposed $9 billion buyout faces opposition from both CoreWeave and Core Scientific shareholders.

Novartis has been proactively striking deals this year to address the impending patent cliff for some of its blockbuster drugs, including Entresto for heart failure, Xolair for asthma and Cosentyx for autoimmune diseases.

D-Wave stock suffered a sell-off after the company announced that it was executing all of its public warrants. When holders move to exercise their warrants in exchange for stock, it will have a dilutive impact on current shareholders.

Applied Digital is in a fast-growing field, supporting data centers. It could be worth buying if you plan to hang on to it for many years.

The acquisition would raise the 2024-2029 expected sales compound annual growth rate for Novartis to 6% from 5%, it said.

UPS is struggling due to tariffs and its decision to reduce its reliance on Amazon. The company has a plan to turn things around.

A Texas wealth advisory sold 172,332 shares of GPIX for an estimated $8.6 million in the third quarter. The transaction value represented 1.1% of the fund's 13F reportable assets under management as of Septembert 30.

FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating that its TissueCypher® Barrett's Esophagus test can provide risk insights beyond pathology alone, influencing clinical management to support earlier intervention for those at higher risk of progression to esophageal cancer and potentially reducing unnecessary procedures for those at lower risk. The research will be presented in three posters at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting, taking place Oct. 27–29, 2025, in Phoenix, Arizona, including one selected for …

Acquired 65,637 shares in a new position, with an estimated transaction value of $8.79 million based on the quarterly average price Post-trade holding: 65,637 shares valued at $8.79 million Lam Research stake places the position outside the fund's top five holdings

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant Health's 2023 ACG abstract, a stu.